Ironwood Pharmaceuticals, Inc.
IRWD
$3.25
-$0.12-3.56%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 296.15M | 338.99M | 308.52M | 317.68M | 351.41M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 296.15M | 338.99M | 308.52M | 317.68M | 351.41M |
| Cost of Revenue | 95.14M | 98.66M | 106.02M | 113.04M | 111.42M |
| Gross Profit | 201.02M | 240.32M | 202.50M | 204.64M | 239.99M |
| SG&A Expenses | 82.26M | 96.55M | 110.76M | 130.93M | 144.27M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 177.39M | 195.22M | 216.78M | 243.97M | 255.69M |
| Operating Income | 118.76M | 143.77M | 91.74M | 73.71M | 95.72M |
| Income Before Tax | 70.03M | 93.57M | 42.91M | 23.97M | 65.20M |
| Income Tax Expenses | 46.01M | 65.02M | 50.80M | 56.31M | 64.32M |
| Earnings from Continuing Operations | 24.02 | 28.55 | -7.89 | -32.34 | 0.88 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 24.02M | 28.55M | -7.89M | -32.34M | 880.00K |
| EBIT | 118.76M | 143.77M | 91.74M | 73.71M | 95.72M |
| EBITDA | 120.64M | 145.68M | 93.68M | 75.69M | 97.73M |
| EPS Basic | 0.15 | 0.17 | -0.05 | -0.20 | 0.01 |
| Normalized Basic EPS | 0.35 | 0.44 | 0.24 | 0.18 | 0.27 |
| EPS Diluted | 0.11 | 0.15 | -0.06 | -0.21 | -0.01 |
| Normalized Diluted EPS | 0.31 | 0.40 | 0.23 | 0.18 | 0.27 |
| Average Basic Shares Outstanding | 647.35M | 644.81M | 642.30M | 639.59M | 636.32M |
| Average Diluted Shares Outstanding | 678.01M | 675.99M | 658.46M | 640.64M | 637.37M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |